Allergy Asthma Respir Dis.  2015 May;3(3):167-172. 10.4168/aard.2015.3.3.167.

Medical treatment according to phenotypes of chronic rhinosinusitis

• Hong SN
• Kim DW

• KMID: 2168485
• DOI: http://doi.org/10.4168/aard.2015.3.3.167

Abstract

Chronic rhinosinusitis is generally divided into 2 types. One is chronic rhinosinusitis with nasal polyps and the other is chronic rhinosinusitis without nasal polyps. However, this classification has the drawbacks no consideration of various immunologic characters of chronic rhinosinusitis and too simple grouping. To compensate for these drawbacks, 1 recent classification has utilized histologic and immunologic parameters to subdivide chronic rhinosinusitis with nasal polyps into that with eosinophilic polyps and that with noneosinophilic nasal polyps. Moreover, phenotyping of chronic rhinosinusitis by using various clinical parameters such as biopsy, computed tomography, and endoscopic findings is very important for the appropriate medical treatment. In this review, before discussing the overall medical treatment of chronic rhinosinusitis, we describe not only clinical characters of chronic rhinosinusitis without nasal polyps but also the immunologic and histologic differentiation of chronic rhinosinusitis cases with eosinophilic and noneosinophilic nasal polyps closely related to the phenotype of chronic rhinosinusitis.

Keyword

Sinusitis; Nasal polyps; Eosinophils; Phenotype; Individualized medicine

MeSH Terms

Biopsy
Classification
Eosinophils
Precision Medicine
Nasal Polyps
Phenotype*
Polyps
Sinusitis

Reference

1. Han JK. Subclassification of chronic rhinosinusitis. Laryngoscope. 2013; 123:Suppl 2. S15–S27.

2. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol. 2009; 124:478–484. 484.e1-2.

3. Kim JW, Hong SL, Kim YK, Lee CH, Min YG, Rhee CS. Histological and immunological features of non-eosinophilic nasal polyps. Otolaryngol Head Neck Surg. 2007; 137:925–930.

4. Steinke JW, Bradley D, Arango P, Crouse CD, Frierson H, Kountakis SE, et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol. 2003; 111:342–349.

5. Yao T, Kojima Y, Koyanagi A, Yokoi H, Saito T, Kawano K, et al. Eotaxin-1, -2, and -3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients. Laryngoscope. 2009; 119:1053–1059.

6. Czerny MS, Namin A, Gratton MA, Antisdel JL. Histopathological and clinical analysis of chronic rhinosinusitis by subtype. Int Forum Allergy Rhinol. 2014; 4:463–469.

7. Ferguson BJ. Categorization of eosinophilic chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2004; 12:237–242.

8. Hellquist HB. Nasal polyps update. Histopathology. Allergy Asthma Proc. 1996; 17:237–242.

9. Norlander T, Bronnegård M, Stierna P. The relationship of nasal polyps, infection, and inflammation. Am J Rhinol. 1999; 13:349–355.

10. Lacroix JS, Zheng CG, Goytom SH, Landis B, Szalay-Quinodoz I, Malis DD. Histological comparison of nasal polyposis in black African, Chinese and Caucasian patients. Rhinology. 2002; 40:118–121.

11. Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010; 126:962–968. 968.e1-6.

12. Van Bruaene N, Perez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008; 121:1435–1441. 1441.e1-3.

13. Umetsu DT, DeKruyff RH. The regulation of allergy and asthma. Immunol Rev. 2006; 212:238–255.

14. Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys C, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004; 114:981–983.

15. Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C. Pathogenesis of chronic rhinosinusitis: inflammation. J Allergy Clin Immunol. 2011; 128:728–732.

16. Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, et al. Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil. Laryngoscope. 2013; 123:E1–E9.

17. Kim DK, Park MH, Chang DY, Eun KM, Shin HW, Mo JH, et al. MBP-positive and CD11c-positive cells are associated with different pheno-types of Korean patients with non-asthmatic chronic rhinosinusitis. PLoS One. 2014; 9:e111352.

18. Saitoh T, Kusunoki T, Yao T, Kawano K, Kojima Y, Miyahara K, et al. Role of interleukin-17A in the eosinophil accumulation and mucosal remodeling in chronic rhinosinusitis with nasal polyps associated with asthma. Int Arch Allergy Immunol. 2010; 151:8–16.

19. Suzuki H, Takahashi Y, Wataya H, Ikeda K, Nakabayashi S, Shimomura A, et al. Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis. J Allergy Clin Immunol. 1996; 98:659–670.

20. Suzuki H, Ikeda K. Mode of action of long-term low-dose macrolide therapy for chronic sinusitis in the light of neutrophil recruitment. Curr Drug Targets Inflamm Allergy. 2002; 1:117–126.

21. Shi J, Fan Y, Xu R, Zuo K, Cheng L, Xu G, et al. Characterizing T-cell phenotypes in nasal polyposis in Chinese patients. J Investig Allergol Clin Immunol. 2009; 19:276–282.

22. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012; (23):3. preceding table of contents, 1-298.

23. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope. 2003; 113:1199–1205.

24. Agius AM. Long-term follow-up of patients with facial pain in chronic rhinosinusitis: correlation with nasal endoscopy and CT. Rhinology. 2010; 48:65–70.

25. Agius AM. Chronic sinusitis in Malta: correlation between symptoms and CT scan. Rhinology. 2010; 48:59–64.

26. Dietz de Loos DA, Hopkins C, Fokkens WJ. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope. 2013; 123:57–63.

27. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012; 130:1049–1062.

28. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012; 67:91–98.

29. Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis: a review of 6,037 patients. J Allergy Clin Immunol. 1977; 59:17–21.

30. Cimmino M, Cavaliere M, Nardone M, Plantulli A, Orefice A, Esposito V, et al. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis. Clin Otolaryngol Allied Sci. 2003; 28:125–132.

31. Salvin RG, Cannon RE, Friedman WH, Palitang E, Sundaram M. Sinusitis and bronchial asthma. J Allergy Clin Immunol. 1980; 66:250–257.

32. Soler ZM, Sauer D, Mace J, Smith TL. Impact of mucosal eosinophilia and nasal polyposis on quality-of-life outcomes after sinus surgery. Otolaryngol Head Neck Surg. 2010; 142:64–71.

33. Snidvongs K, Chin D, Sacks R, Earls P, Harvey RJ. Eosinophilic rhinosinusitis is not a disease of ostiomeatal occlusion. Laryngoscope. 2013; 123:1070–1074.

34. Takeno S, Hirakawa K, Ishino T. Pathological mechanisms and clinical features of eosinophilic chronic rhinosinusitis in the Japanese population. Allergol Int. 2010; 59:247–256.

35. Sakuma Y, Ishitoya J, Komatsu M, Shiono O, Hirama M, Yamashita Y, et al. New clinical diagnostic criteria for eosinophilic chronic rhinosinusitis. Auris Nasus Larynx. 2011; 38:583–588.

36. Moriyama H, Yanagi K, Ohtori N, Fukami M. Evaluation of endoscopic sinus surgery for chronic sinusitis: post-operative erythromycin therapy. Rhinology. 1995; 33:166–170.

37. Nakayama T, Yoshikawa M, Asaka D, Okushi T, Matsuwaki Y, Otori N, et al. Mucosal eosinophilia and recurrence of nasal polyps - new classification of chronic rhinosinusitis. Rhinology. 2011; 49:392–396.

38. Mullol J, Xaubet A, Lopez E, Roca-Ferrer J, Picado C. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax. 1995; 50:270–274.

39. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006; 117:522–543.

40. Snidvongs K, Kalish L, Sacks R, Sivasubramaniam R, Cope D, Harvey RJ. Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis. Am J Rhinol Allergy. 2013; 27:221–233.

41. Grobler A, Weitzel EK, Buele A, Jardeleza C, Cheong YC, Field J, et al. Pre- and postoperative sinus penetration of nasal irrigation. Laryngoscope. 2008; 118:2078–2081.

42. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012: a summary for otorhinolaryngologists. Rhinology. 2012; 50:1–12.

43. Wen W, Liu W, Zhang L, Bai J, Fan Y, Xia W, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol. 2012; 129:1522–1528.e5.

44. Howard BE, Lal D. Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis. Curr Allergy Asthma Rep. 2013; 13:236–243.

45. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012; 22:1–12.

46. Namyslowski G, Misiolek M, Czecior E, Malafiej E, Orecka B, Namyslowski P, et al. Comparison of the efficacy and tolerability of amoxycillin/clavulanic acid 875 mg b.i.d. with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults. J Chemother. 2002; 14:508–517.

47. Legent F, Bordure P, Beauvillain C, Berche P. A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy. 1994; 40:Suppl 1. 8–15.

48. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010; 125:1069–1076.e4.

49. Kadota J, Mukae H, Tomono K, Kohno S, Nasu M. Efficacy of long-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between HLA-B54-positive and -negative cases. Int J Antimicrob Agents. 2004; 24:550–554.

50. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006; 116:189–193.

51. Videler WJ, Badia L, Harvey RJ, Gane S, Georgalas C, van der Meulen FM, et al. Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy. 2011; 66:1457–1468.

52. Pynnonen MA, Mukerji SS, Kim HM, Adams ME, Terrell JE. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg. 2007; 133:1115–1120.

53. Raza T, Elsherif HS, Zulianello L, Plouin-Gaudon I, Landis BN, Lacroix JS. Nasal lavage with sodium hypochlorite solution in Staphylococcus aureus persistent rhinosinusitis. Rhinology. 2008; 46:15–22.

54. Weissman JD, Fernandez F, Hwang PH. Xylitol nasal irrigation in the management of chronic rhinosinusitis: a pilot study. Laryngoscope. 2011; 121:2468–2472.

55. Videler WJ, van Drunen CM, Reitsma JB, Fokkens WJ. Nebulized bacitracin/colimycin: a treatment option in recalcitrant chronic rhinosinusitis with Staphylococcus aureus? A double-blind, randomized, placebo-controlled, cross-over pilot study. Rhinology. 2008; 46:92–98.

56. Liang KL, Su MC, Shiao JY, Tseng HC, Hsin CH, Lin JF, et al. Amphotericin B irrigation for the treatment of chronic rhinosinusitis without nasal polyps: a randomized, placebo-controlled, double-blind study. Am J Rhinol. 2008; 22:52–58.

57. Kennedy DW, Kuhn FA, Hamilos DL, Zinreich SJ, Butler D, Warsi G, et al. Treatment of chronic rhinosinusitis with high-dose oral terbinafine: a double blind, placebo-controlled study. Laryngoscope. 2005; 115:1793–1799.

58. Wong IW, Omari TI, Myers JC, Rees G, Nair SB, Jamieson GG, et al. Nasopharyngeal pH monitoring in chronic sinusitis patients using a novel four channel probe. Laryngoscope. 2004; 114:1582–1585.

59. Jecker P, Orloff LA, Wohlfeil M, Mann WJ. Gastroesophageal reflux disease (GERD), extraesophageal reflux (EER) and recurrent chronic rhinosinusitis. Eur Arch Otorhinolaryngol. 2006; 263:664–667.

60. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001; 31:1385–1391.

61. Pauli C, Fintelmann R, Klemens C, Hilgert E, Jund F, Rasp G, et al. Polyposis nasi: improvement in quality of life by the influence of leukotrien receptor antagonists. Laryngorhinootologie. 2007; 86:282–286.

62. Stewart RA, Ram B, Hamilton G, Weiner J, Kane KJ. Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis. Otolaryngol Head Neck Surg. 2008; 139:682–687.

63. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010; 48:318–324.

64. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006; 118:1133–1141.

65. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011; 128:989–995.e1-8.